SPRINGFIELD, Ill. – State Rep. Theresa Mah, D-Chicago, is working to cap insulin costs for patients as part of her work to lower prescription drug prices for Illinoisans.
“It is wrong for patients in need of insulin treatments to be priced out of lifesaving health care,” Mah said. “In Illinois, we will put an end to large insurance corporations and prescription drug companies putting profits ahead of people.”
To ensure that individuals in need of insulin do not face outrageous out-of-pocket costs, Mah is sponsoring Senate Bill 667 to cap co-payments for insulin at $100 per month. Mah’s measure would also direct the Illinois Attorney General’s Office to investigate and report on additional consumer protections for insulin pricing. Mah’s legislation would make Illinois the second state after Colorado to cap out-of-pocket costs for insulin treatments.
“Building a stronger Illinois means lowering prescription drug prices for patients and protecting critical health care access,” Mah said. “No person should be forced to choose between having lifesaving insulin and keeping a roof over their head or putting food on their table. This measure will help ensure that drug companies aren’t putting patients in a bind by charging outrageous and unreasonable prices.”
Mah represents the 2nd District, which includes the Chicago neighborhoods of Back of the Yards, Bridgeport, Brighton Park, Chinatown, McKinley Park, and Pilsen.